Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis

KB Bouker, TC Skaar, RB Riggins… - …, 2005 - academic.oup.com
KB Bouker, TC Skaar, RB Riggins, DS Harburger, DR Fernandez, A Zwart, A Wang
Carcinogenesis, 2005academic.oup.com
We have directly assessed the ability of interferon regulatory factor-1 (IRF-1) to act as a
tumor suppressor gene in human breast cancer cells and explored whether this suppressor
function is mechanistically conferred by affecting cell cycle transition, apoptosis and/or
caspase activation. We have used a dual approach, measuring whether overexpression of
wild-type IRF-1 or a dominant negative IRF-1 (dnIRF-1) produce opposing effects on breast
cancer cell proliferation in vitro or tumorigenicity in athymic nude mice. Mechanistic studies …
Abstract
We have directly assessed the ability of interferon regulatory factor-1 (IRF-1) to act as a tumor suppressor gene in human breast cancer cells and explored whether this suppressor function is mechanistically conferred by affecting cell cycle transition, apoptosis and/or caspase activation. We have used a dual approach, measuring whether overexpression of wild-type IRF-1 or a dominant negative IRF-1 (dnIRF-1) produce opposing effects on breast cancer cell proliferation in vitro or tumorigenicity in athymic nude mice. Mechanistic studies determined the effects of blocking endogenous IRF-1 expression on cell cycle transition by flow cytometry, on apoptosis by Annexin V staining, and on caspase activation by fluorescent substrate cleavage. IRF-1 mRNA ( P ≤ 0.001) and protein ( P ≤ 0.001) are highly expressed in non-tumorigenic, normal, mammary epithelial cells, with intermediate expression in tumorigenic, but non-metastatic, cells and very low expression in metastatic cell lines. In MCF-7 cells transfected with a wild-type IRF-1 (MCF-7/IRF-1), IRF-1 mRNA expression inversely correlates with the rate of cell proliferation ( r = −0.91; P = 0.002). Conversely, expression of dnIRF-1 in both MCF-7 (MCF-7/dnIRF-1; p53 wild-type) and T47D cells (T47D/dnIRF-1; p53 mutant) increases cell proliferation ( P ≤ 0.001). In athymic nude mice, the incidence of MCF-7/IRF-1 xenografts is reduced ( P = 0.045), whereas MCF-7/dnIRF-1 xenografts exhibit a significantly higher tumor incidence ( P ≤ 0.001). Effects of IRF-1/dnIRF-1 are mediated through changes in the rates of apoptosis and not through cell cycle regulation. MCF-7/dnIRF-1 cells exhibit a 50% decrease in basal apoptosis ( P = 0.007) and a significant reduction in caspase 8 activity ( P = 0.03); similar effects occur in T47D/dnIRF-1 cells, where the effects on apoptosis appear to be mediated through inhibition of caspases 3/7 ( P < 0.001) and caspase 8 ( P = 0.03). These data establish a functional role for IRF-1 in the growth suppression of breast cancer cells and strongly implicate IRF-1 as a tumor suppressor gene in breast cancer that acts, independent of p53, to control apoptosis.
Oxford University Press